1. Home
  2. BLIN vs KPRX Comparison

BLIN vs KPRX Comparison

Compare BLIN & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgeline Digital Inc.

BLIN

Bridgeline Digital Inc.

N/A

Current Price

$0.85

Market Cap

9.2M

Sector

Technology

ML Signal

N/A

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

N/A

Current Price

$2.04

Market Cap

8.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BLIN
KPRX
Founded
2000
1998
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
8.0M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BLIN
KPRX
Price
$0.85
$2.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.62
$10.00
AVG Volume (30 Days)
31.9K
22.2K
Earning Date
02-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,568,000.00
N/A
Revenue This Year
$22.67
N/A
Revenue Next Year
$21.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$1.76
52 Week High
$2.22
$4.18

Technical Indicators

Market Signals
Indicator
BLIN
KPRX
Relative Strength Index (RSI) 47.01 46.72
Support Level $0.69 $1.96
Resistance Level $0.87 $2.21
Average True Range (ATR) 0.05 0.09
MACD -0.01 -0.00
Stochastic Oscillator 12.51 34.62

Price Performance

Historical Comparison
BLIN
KPRX

About BLIN Bridgeline Digital Inc.

Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: